Find Out if Lecanemab Is the Hero Aducanumab Wasn’t
April 2023
You’ll hear buzz about a new Alzheimer’s med, lecanemab (Leqembi).
It joins aducanumab (Aduhelm) as the second IV monoclonal antibody to treat mild Alzheimer’s disease. It’s NOT for dementia without amyloid beta plaque or more severe disease.
Aducanumab and lecanemab are being touted as “disease-modifying” because they decrease amyloid plaque. But this surrogate marker isn’t shown to improve Alzheimer’s disease yet.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote